Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

PURPOSE: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Support Care Cancer
Autors principals: Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669370/
https://ncbi.nlm.nih.gov/pubmed/26335402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-2904-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars